TENAX THERAPEUTICS, INC. Proceeds from Issuance of Medium-term Notes
TENAX THERAPEUTICS, INC. (TENX) reported Proceeds from Issuance of Medium-term Notes of $549.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfMediumTermNotes · last filed 2025-03-25
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for the quarter ending 2023-03-31 was $693.67K, a 90.28% increase year-over-year.
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for the quarter ending 2022-03-31 was $364.55K.
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for the quarter ending 2021-03-31 was $0.00.
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for fiscal 2023 was $549.00K, a 20.86% decline from fiscal 2022.
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for fiscal 2022 was $693.67K.
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- TENAX THERAPEUTICS, INC. proceeds from issuance of medium-term notes for fiscal 2020 was $244.66K.
| Period end | Proceeds from Issuance of Medium-term Notes 3 month | Proceeds from Issuance of Medium-term Notes 6 month | Proceeds from Issuance of Medium-term Notes 9 month | Proceeds from Issuance of Medium-term Notes 12 month | Proceeds from Issuance of Medium-term Notes 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $549.00K 10-K · filed 2025-03-25 | $548.75K 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $693.67K 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $693.67K 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $693.67K 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $693.67K 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $364.55K 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $364.55K 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $364.55K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $0.00 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $244.66K 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $244.66K 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $244.66K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |